Correction: Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets (PLoS ONE (2013) 8, 12 (e84883) DOI: 10.1371/journal.pone.0084883);Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Girolamo, Francesco ^a   Dallatomasina, Alice ^b   Rizzi, Marco ^a   Errede, Mariella ^a   Wälchli, Thomas ^d,e   Mucignat, Maria Teresa ^c   Frei, Karl ^e   Roncali, Luisa ^a   Perris, Roberto ^b,c   Virgintino, Daniela ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CSPG4 PROTEIN; ISOPROTEIN; MONOCLONAL ANTIBODY; NG2 PROTEIN; PROTEOGLYCAN; UNCLASSIFIED DRUG; CANCER ANTIBODY; CSPG4 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEOCHONDROITIN SULFATE; TUMOR PROTEIN;

ARTICLE; BASEMENT MEMBRANE; BRAIN BLOOD VESSEL; BRAIN TISSUE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; MOUSE; NEWBORN; NONHUMAN; PERICYTE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR CELL LINE; ADULT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BRAIN; BRAIN TUMOR; CHEMISTRY; CLINICAL TRIAL; FETUS; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MULTICENTER STUDY; PATHOLOGY;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHONDROITIN SULFATE PROTEOGLYCANS; FEMALE; FETUS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; PERICYTES; PROTEIN ISOFORMS;

EID: 84893502819     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095120     Document Type: Erratum

References (65)

1. Vajkoczy P, Menger MD (2000) Vascular microenvironment in gliomas. J Neurooncol 50: 99-108. doi:10.1023/A:1006474832189. PubMed: 11245285. (Pubitemid 32166294)
2. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489. PubMed: 15977639. (Pubitemid 40781150)
3. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710. doi:10.1101/gad.1596707. PubMed: 17974913. (Pubitemid 350070717)
4. Leon SP, Folkerth RD, Black PM (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77: 362-372. doi:10.1002/(SICI)1097-0142(19960115)77:2. PubMed: 8625246. (Pubitemid 26023356)
5. Liu XM, Zhang QP, Mu YG, Zhang XH, Sai K et al. (2011) Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol 105: 173-179. doi:10.1007/s11060-011-0578-5. PubMed: 21533525.
6. Kleihues P, Soylemezoglu F, Schäuble B, Scheithauer BW, Burger PC (1995) Histopathology, classification, and grading of gliomas. Glia 15: 211-221. doi:10.1002/glia.440150303. PubMed: 8586458.
7. Hardee ME, Zagzag D (2012) Mechanisms of Glioma-Associated Neovascularization. Am J Pathol 181: 1126-1141. doi:10.1016/j.ajpath.2012.06. 030. PubMed: 22858156.
8. Plate KH, Scholz A, Dumont DJ (2012) Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol 124: 763-775. doi:10.1007/s00401-012-1066-5. PubMed: 23143192.
9. Tung JJ, Tattersall IW, Kitajewski J (2012) Tips, stalks, tubes: Notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. Cold Spring Harb Perspect Med 4: 1-14. PubMed: 22355796.
10. Stiver SI (2004) Angiogenesis and its role in the behavior of astrocytic brain tumors. Front Biosci 9: 3105-3123. doi:10.2741/1463. PubMed: 15353341.
11. Chekenya M, Rooprai HK, Davies D, Levine JM, Butt AM et al. (1999) The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. Int J Dev Neurosci 17: 421-435. doi:10.1016/S0736-5748(99)00019- 2. PubMed: 10571405. (Pubitemid 29421830)
12. Chekenya M, Pilkington GJ (2002) NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours. J Neurocytol 31: 507-521. doi:10.1023/A:1025795715377. PubMed: 14501220. (Pubitemid 37378262)
13. Wiranowska M, Ladd S, Smith SR, Gottschall PE (2006) CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma. Brain. Cell Biol 35: 159-172. (Pubitemid 47630628)
14. Stallcup WB, Huang FJ (2008) A role for the NG2 proteoglycan in glioma progression. Cell Adh Migr 2: 192-201. doi:10.4161/cam.2.3.6279. PubMed: 19262111.
15. Al-Mayhani MT, Grenfell R, Narita M, Piccirillo S, Kenney-Herbert E et al. (2011) NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro Oncol 13: 830-845. doi:10.1093/neuonc/nor088. PubMed: 21798846.
16. Svendsen A, Verhoeff JJ, Immervoll H, Brøgger JC, Kmiecik J et al. (2011) Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 122: 495-510. doi:10.1007/s00401-011-0867-2. PubMed: 21863242.
17. Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo KO et al. (2011) Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLOS ONE 6: e23062. doi:10.1371/journal. pone.0023062. PubMed: 21829586.
18. Schlingemann RO, Rietveld FJR, de Waal RMW, Ferrone S, Ruiter DJ (1990) Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136: 1393-1405. PubMed: 1694058. (Pubitemid 20210338)
19. Shoshan Y, Nishiyama A, Chang A, Mörk S, Barnett GH et al. (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: Implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A 96: 10361-10366. doi:10.1073/pnas.96.18.10361. PubMed: 10468613. (Pubitemid 29422563)
20. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y (2008) Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 68: 8066-8075. doi:10.1158/0008-5472.CAN-08-0287. PubMed: 18829565.
21. Chekenya M, Enger PØ, Thorsen F, Tysnes BB, Al-Sarraj S et al. (2002) The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol 28: 367-380. doi:10.1046/j. 1365-2990.2002.00412.x. PubMed: 12366818.
22. Ozerdem U, Stallcup WB (2003) Early contribution of pericytes to angiogenic sprouting and tube formation. Angiogenesis 6: 241-249. doi:10.1023/B:AGEN.0000021401.58039.a9. PubMed: 15041800. (Pubitemid 38506669)
23. Ozerdem U, Stallcup WB (2004) Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 7: 269-276. doi:10.1007/s10456-004-4182-6. PubMed: 15609081.
24. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G (2005) PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7(9): 870-879. doi:10.1038/ncb1288. PubMed: 16113679. (Pubitemid 41486287)
25. Huang FJ, You WK, Bonaldo P, Seyfried TN, Pasquale EB et al. (2010) Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Dev Biol 344: 1035-1046. doi:10.1016/j.ydbio.2010.06.023. PubMed: 20599895.
26. Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo KO et al. (2011) Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLOS ONE 6: e23062. doi:10.1371/journal. pone.0023062. PubMed: 21829586.
27. Poli A, Wang J, Domingues O, Planagumà J, Yan T et al. (2013) Targeting glioblastoma with NK cells and mAb against NG2/ CSPG4 prolongs animal survival. Oncotarget 4: 1507-1526. PubMed: 24096697.
28. Terrile M, Appolloni I, Calzolari F, Perris R, Tutucci E et al. (2010) PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2. BMC Cancer 10: 550. doi:10.1186/1471-2407-10-550. PubMed: 20939912.
29. Barrantes-Freer A, Kim E, Bielanska J, Giese A, Mortensen LS et al. (2013) Human glioma-initiating cells show a distinct immature phenotype resembling but not identical to NG2 glia. J Neuropathol Exp Neurol 72: 307-324. doi:10.1097/NEN.0b013e31828afdbd. PubMed: 23481707.
30. Sugiarto S, Persson AI, Munoz EG, Waldhuber M, Lamagna C et al. (2011) Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell 20: 328-340. doi:10.1016/j.ccr.2011.08.011. PubMed: 21907924.
31. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ (2010) Non-stem origin for oligodendroglioma. Cancer Cell 18: 669-682. doi:10.1016/j.ccr.2010. 10.033. PubMed: 21156288.
32. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T et al. (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338: 1080-1084. doi:10.1126/science.1226929. PubMed: 23087000.
33. Virgintino D, Errede M, Rizzi M, Girolamo F, Strippoli M et al. (2013) The CXCL12/CXCR4/CXCR7 ligand-receptor system regulates neuro-glio-vascular interactions and vessel growth during human brain development. J Inherit Metab Dis 36: 455-466. doi:10.1007/s10545-012-9574-y. PubMed: 23344887.
34. Virgintino D, Girolamo F, Errede M, Capobianco C, Robertson D et al. (2007) An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis. Angiogenesis 10: 35-45. doi:10.1007/s10456-006-9061-x. PubMed: 17225955. (Pubitemid 46356222)
35. Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJF (2004) Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain. Res Rev 45: 143-163. doi:10.1016/j.brainresrev.2004. 03.001. (Pubitemid 38802868)
36. Bian XW, Wang QL, Xiao HL, Wang JM (2006) Tumor microvascular architecture phenotype (T-MAP) as a new concept for studies of angiogenesis and oncology. J Neurooncol 80: 211-213. doi:10.1007/s11060-006-9167-4. PubMed: 16708278.
37. Girolamo F, Virgintino D, Errede M, Capobianco C, Bernardini N et al. (2004) Involvement of metalloprotease-2 in the development of human brain microvessels. Histochem Cell Biol 122: 261-270. doi:10.1007/s00418-004-0705-x. PubMed: 15375663. (Pubitemid 39371495)
38. Duff SE, Li C, Garland JM, Kumar S (2003) CD 105 is important for angiogenesis: evidence and potential applications. FASEB J 17: 984-992. doi:10.1096/fj.02-0634rev. PubMed: 12773481. (Pubitemid 36676386)
39. ten Dijke P, Goumans M-J, Pardali E (2008) Endoglin in angiogenesis and vascular diseases. Angiogenesis 11: 79-89. doi:10.1007/s10456-008-9101-9. PubMed: 18283546.
40. Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E et al. (2013) Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 210: 563-579. doi:10.1084/jem.20120662. PubMed: 23401487.
41. Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q et al. (2012) CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 120: 2330-2339. doi:10.1182/blood-2012-01-406108. PubMed: 22718841.
42. Simonavicius N, Robertson D, Bax DA, Jones C, Huijbers IJ (2008) Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 21: 308-315. doi:10.1038/modpathol.3801006. PubMed: 18192970. (Pubitemid 351304285)
43. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163: 1801-1815. doi:10.1016/S0002-9440(10)63540-7. PubMed: 14578181. (Pubitemid 37310012)
44. Mancuso P, Martin-Padura I, Calleri A, Marighetti P, Quarna J (2011) Circulating perivascular progenitors: a target of PDGFR inhibition. Int J Cancer 129: 1344-1350. doi:10.1002/ijc.25816. PubMed: 21128230.
45. Jakovcevski I, Filipovic R, Mo Z, Rakic S, Zecevic N (2009) Oligodendrocyte development and the onset of myelination in the human fetal brain. Frontiers in Neuroanat 3: 1-15. (Pubitemid 350172726)
46. Girolamo F, Ferrara G, Strippoli M, Rizzi M, Errede M et al. (2011) Cerebral cortex demyelination and oligodendrocyte precursor response to experimental autoimmune encephalomyelitis. Neurobiol Dis 43: 678-689. doi:10.1016/j.nbd.2011.05.021. PubMed: 21679768.
47. Liu Y, Wu Y, Lee JC, Xue H, Pevny LH et al. (2002) Oligodendrocyte and astrocyte development in rodents: an in situ and immunohistological analysis during embryonic development. Glia 40: 25-43. doi:10.1002/glia.10111. PubMed: 12237841. (Pubitemid 35181341)
48. Fadini GP, Mancuso P, Bertolini F, de Kreutzenberg S, Avogaro A (2012) Amelioration of glucose control mobilizes circulating pericyte progenitor cells in Type 2 diabetic patients with microangiopathy. Exp Diabetes Res 2012: 1-8.
49. Virgintino D, Ozerdem U, Girolamo F, Roncali L, Stallcup WB et al. (2008) Reversal of cellular roles in angiogenesis: Implications for anti-angiogenic therapy. J Vasc Res 45: 129-131. doi:10.1159/000109965. PubMed: 17943023. (Pubitemid 351651298)
50. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C et al. (2010) A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133: 973-982. doi:10.1093/brain/awq044. PubMed: 20375132.
51. Au P, Tam J, Fukumura D, Jain RK (2008) Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 11: 4551-4558. PubMed: 18256324.
52. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S et al. (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153: 139-152. doi:10.1016/j.cell.2013.02.021. PubMed: 23540695.
53. Zhang H, Zhang X, Bie P, Miller RH, Bai L (2013) Adult NG2-expressing cells in multiple organs: A novel progenitor in regenerative medicine. J Genet Syndr Gene Ther S3: 008.
54. Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE (2010) NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron 68: 668-681. doi:10.1016/j.neuron. 2010.09.009. PubMed: 21092857.
55. Hughes EG, Kang SH, Fukaya M, Bergles DE (2013) Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. Nat Neurosci 16: 668-676. doi:10.1038/nn.3390. PubMed: 23624515.
56. Wei J-H, Seemann J (2009) The mitotic spindle mediates inheritance of the Golgi ribbon structure. J Cell Biol 184: 391-397. doi:10.1083/jcb.200809090. PubMed: 19188490.
57. Shandala T, Parkinson-Lawrence EJ, Brooks DA (2011) Protein: cotranslational and posttranslational modification in organelles John Wiley & Sons, Ltd. doi:10.1002/9780470015902.a0005716.
58. Lippoldt A, Kniesel U, Liebner S, Kalbacher H, Kirsch T et al. (2000) Structural alterations of tight junctions are associated with loss of polarity in stroke-prone spontaneously hypertensive rat blood-brain barrier endothelial cells. Brain Res 885: 251-261. doi:10.1016/S0006-8993(00)02954-1. PubMed: 11102579.
59. Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y et al. (2002) Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst 94: 1080-1091. doi:10.1093/jnci/94.14.1080. PubMed: 12122099. (Pubitemid 34830728)
60. Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G, Liebner S et al. (2003) Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol 105: 586-592. PubMed: 12734665. (Pubitemid 36798859)
61. Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR et al. (2011) Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLOS ONE 6: e23205. doi:10.1371/journal.pone.0023205. PubMed: 21826239.
62. Adekola K, Rosen ST, Shanmugam M (2012) Glucose transporters in cancer metabolism. Curr Opin Oncol 24: 650-654. doi:10.1097/CCO.0b013e328356da72. PubMed: 22913968.
63. Ishihara H, Kubota H, Lindberg RLP, Leppert D, Gloor SM et al. (2008) Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor β2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol 67: 435-448. doi:10.1097/NEN. 0b013e31816fd622. PubMed: 18431253. (Pubitemid 351653535)
64. Sanderson RD, Yang Y (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25: 149-159. doi:10.1007/s10585- 007-9125-3. PubMed: 18027090.
65. Couchman JR (2010) Transmembrane Signaling Proteoglycans. Annu Rev Cell Dev Biol 26: 89-114. doi:10.1146/annurev-cellbio-100109-104126. PubMed: 20565253.